
|Articles|March 9, 2011
- December 2010
- Volume 4
- Issue 12
FDA Approves Zactima
Author(s)OBTN
An FDA advisory panel voted 10 to 0 in favor of approving Zactima (vandetanib) for patients with medullary thyroid cancer who have symptomatic, progressive disease.
Advertisement
An FDA advisory panel voted 10 to 0 in favor of approving Zactima (vandetanib) for patients with medullary thyroid cancer who have symptomatic, progressive disease. The panel expressed concerns about “substantial” drug-related toxicity associated with the 300-mg daily dose. Members said that patients taking Zactima appeared to be at greater risk for stroke and other cerebrovascular events and a prolonged QT interval.
Articles in this issue
almost 15 years ago
Medulloblastoma Subtypes Are Different Diseasesalmost 15 years ago
ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myelomaalmost 15 years ago
FDA Requests Label Change for Generic DocetaxelAdvertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5



































